Review
Copyright ©The Author(s) 2016.
World J Gastroenterol. Sep 14, 2016; 22(34): 7645-7659
Published online Sep 14, 2016. doi: 10.3748/wjg.v22.i34.7645
Table 1 Variables included in the most widely used hepatocellular carcinoma staging systems
Staging systemAscitesTumor burdenAlbuminBilirubinINRHEAFPPVTEHSPSALP
OkudaYesYesYesYesNoNoNoNoNoNoNo
CLIPYesYesYesYesYesYesYesYesNoNoNo
BCLCYesYesYesYesYesYesNoYesYesYesNo
GRETCHNoNoNoYesNoNoYesYesNoYesYes
TNM 7th editionNoYesNoNoNoNoNoYesYesNoNo
Table 2 Results of studies with molecular targeted therapies as first line in advanced hepatocellular carcinoma
TreatmentTrialOSTTPRef.
SorafenibPhase III vs placebo10.7 mo vs 7.9 mo, P < 0.001;5.5 mo vs 2.8 mo, P < 0.001[10]
(SHARP)HR = 0.69; 95%CI: 0.55-0.87
SorafenibPhase III vs placebo6.5 mo vs 4.2 mo, P = 0.014;2.8 mo vs 1.4 mo, P = 0.0005;[11]
(Asia-Pacific)HR = 0.68; 95%CI: 0.50-0.93HR = 0.57; 95%CI: 0.42-0.79
SunitinibPhase III vs sorafenib7.9 mo vs 10.2 mo, P = 0.0019; HR = 1.30; 95%CI: 1.13-1.504.1 mo vs 3.8 mo, one-sided P = 0.8312;[31]
(SUN)two-sided P = 0.3082; HR = 1.13
BrivanibPhase III vs sorafenib9.5 mo vs 9.9 mo, P = 0.3116;4.2 mo vs 4.1 mo, P = 0.853;[32]
(BRISK-FL)HR = 1.07; 95%CI: 0.94-1.23HR = 1.01; 95%CI: 0.88-1.16
LinifanibPhase III vs sorafenib9.1 mo vs 9.8 mo, P = NS;5.4 mo vs 4.0 mo, P = 0.001;[33]
HR = 1.05; 95%CI: 0.90-1.22HR = 0.759; 95%CI: 0.64-0.895
ErlotinibPhase III erlotinib plus sorafenib and eorafenib plus placebo (SEARCH)9.5 mo vs 8.5 mo, P = 0.408;3.2 mo vs 4.0 mo, P = NS;[36]
HR = 0.929HR = 1.135; P = 0.18
Table 3 Results of studies with molecular targeted therapies as second line in advanced hepatocellular carcinoma
TreatmentTrialOSTTP/PFSRef.
BrivanibBrivanib vs placebo (BRISK-PS)9.4 mo vs 8.2 mo, P = 0.3307;4.2 mo vs 2.7 mo, P < 0.001;[42]
HR = 0.89; 95%CI: 0.69-1.15HR = 0.56; 95%CI: 0.42-0.76
EverolimusEverolimus vs placebo (EVOLVE-1)7.6 mo vs 7.3 mo, P = 0.68;3.0 mo vs 2.6 mo, P = 0.01;[44]
HR = 1.05; 95%CI: 0.86-1.27HR = 0.93; 95%CI: 0.75-1.15
RamucirumabRamucirumab vs placebo (REACH)9.2 mo vs 7.6 mo, P = 0.14;2.8 mo vs 2.1 mo, P < 0.0001;[45]
HR = 0.87; 95%CI: 0.72-1.05HR = 0.63; 95%CI: 0.52-0.75
Table 4 Principal ongoing studies in advanced hepatocellular carcinoma with new molecular targeted therapies
StudyDrugStatus
A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (e7080) vs sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinomaLenvatinib vs sorafenibActive, not recruiting
Study of regorafenib after sorafenib in patients with hepatocellular carcinoma (RESORCE)Regorafenib vs placeboRecruiting
A study of dovitinib vs sorafenib in adult patients with hepatocellular carcinoma as a first line treatmentDovitinib vs sorafenibCompleted (phase 2)
A study of nivolumab vs sorafenib as first-line treatment in patients with advanced hepatocellular carcinomaNivolumab vs sorafenibRecruiting
Table 5 Assessment of target lesion response: Conventional Response Evaluation Criteria in Solid Tumors and modified Response Evaluation Criteria in Solid Tumors assessment for hepatocellular carcinoma following the American Association for the Study of Liver Diseases-Journal of the National Cancer Institute guideline
RECISTmRECIST
CR: Disappearance of all target lesions.CR: Disappearance of any intratumoral arterial enhancement in all target lesions.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions.PR: At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions.
SD: Any cases that do not qualify for either partial response or progressive disease.SD: Any cases that do not qualify for either partial response or progressive disease.
PD: An increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started.PD: An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started.